grifols

The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of 2012 was €133.5 million, seven times that of the previous year. The company’s success is attributed to its wide geographical consumer base and the recent purchase of US based Talecris Plasma Resources.

The Catalan pharmaceutical company Grífols, third worldwide company in plasma derivatives, has signed a cooperation agreement with the Shanghai Blood Bank. The agreement, which strengthens the presence of the Catalan company in China, promotes blood genotyping research. The Chinese institution will use the Grifols’ genetic test BLOODchip in transfusion compatibility studies. Shanghai Blood Bank serves over 20 million people and receives more than 300.000 donations per year. In 2011, Grifols sales in China grew by 30%.

The Federation of Blood Donors in Catalonia wants to reach the young population and to raise the number of donations. Besides, the Catalan pharmaceutical company Grifols asked for a change in the law in order to pay for giving blood. This measure would be an incentive to increase the stock of plasma.

The Catalan pharmaceutical company is the world’s leader in blood-derived products. After expanding in the United States by purchasing Talecris, Grifols needed a larger headquarters. It moved to three interconnected buildings in Sant Cugat del Vallès, in Barcelona’s Metropolitan Area. From the new facilities, Grifols will investigate stem cells and Alzheimer’s.

The Catalan pharmaceutical and chemical company was identified in a Wikileaks cable from the U.S. State Department as one of three strategic items the United States had in Spain, together with the natural gas pipeline from Algeria and the Gibraltar Strait. Grifols leads the blood plasma-based products’ market in Europe and is expanding its U.S. presence.